IRLAB Therapeutics AB (publ) logo

IRLAB Therapeutics AB (publ)

SSE:IRLAB-A.ST

Overview | Financials
Company Name IRLAB Therapeutics AB (publ)
Symbol IRLAB-A.ST
Currency SEK
Price 14.45
Market Cap 748,345,270
Dividend Yield 0%
52-week-range 5.58 - 18
Industry Biotechnology
Sector Healthcare
CEO Mr. Gunnar Olsson
Website https://www.irlab.se

An error occurred while fetching data.

About IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and

Related Stocks

Doxa AB (publ) logo

Doxa AB (publ)

DOXA.ST

3.2 SEK

Intervacc AB (publ) logo

Intervacc AB (publ)

IVACC.ST

3.735 SEK

Mentice AB (publ) logo

Mentice AB (publ)

MNTC.ST

34.4 SEK

Xbrane Biopharma AB (publ) logo

Xbrane Biopharma AB (publ)

XBRANE.ST

2.085 SEK

Vicore Pharma Holding AB (publ) logo

Vicore Pharma Holding AB (publ)

VICO.ST

14.38 SEK

RaySearch Laboratories AB (publ) logo

RaySearch Laboratories AB (publ)

RAY-B.ST

92.2 SEK

Elos Medtech AB (publ) logo

Elos Medtech AB (publ)

ELOS-B.ST

203 SEK

Humana AB (publ) logo

Humana AB (publ)

HUM.ST

27 SEK

Q-linea AB (publ) logo

Q-linea AB (publ)

QLINEA.ST

2.49 SEK

Isofol Medical AB (publ) logo

Isofol Medical AB (publ)

ISOFOL.ST

0.616 SEK

Financials

Numbers are in millions USD

Numbers are in millions USD